TMS and SPRAVATO are different treatments for treatment-resistant depression. TMS uses noninvasive magnetic brain stimulation, while SPRAVATO uses supervised intranasal esketamine. Current comparative evidence does not establish one treatment as universally better.
Effectiveness is only one part of the decision. Treatment speed, side effects, medical history, appointment burden, transportation, maintenance, insurance, and individual preferences can also affect treatment fit.
Transcranial Magnetic Stimulation (TMS), particularly repetitive TMS (rTMS), is a non-drug brain-stimulation treatment. SPRAVATO® is an FDA-approved esketamine nasal spray. Both treatments can enter the discussion when standard depression treatment has not provided adequate relief.
The table below provides a quick orientation before each difference is examined in detail.
| Attribute | TMS | SPRAVATO |
| Treatment type | Noninvasive brain stimulation | Prescription esketamine medication |
| Delivery | Magnetic pulses through a treatment coil | Intranasal spray |
| Drug exposure | No drug is administered as the TMS treatment | Pharmacologic treatment |
| Setting | Outpatient clinical setting | Certified healthcare setting |
| Initial schedule | Repeated sessions over several weeks; protocol dependent | Twice weekly during weeks 1–4 |
| Post-treatment monitoring | No SPRAVATO-style REMS observation | At least 2 hours |
| Driving | Standard TMS generally has no medication-related next-day driving restriction | No driving until the next day after restful sleep |
| Common side-effect pattern | Mainly scalp, head, or local stimulation effects | Psychoactive and systemic effects can occur |
| Maintenance | Follow-up or retreatment varies | Continued dosing can be individualized |
| Universal efficacy winner | Not established | Not established |
NIMH describes standard rTMS as five sessions per week for approximately four to six weeks, with sessions lasting about 3–40 minutes. Current SPRAVATO labeling uses twice-weekly treatment during weeks 1–4, weekly treatment during weeks 5–8, then weekly or every two weeks when continued treatment is appropriate.
The practical differences are substantial, but neither treatment can be selected from a table alone. Individual treatment fit requires psychiatric assessment.
What Is the Main Difference Between TMS and Spravato?
The main difference between TMS and SPRAVATO is treatment modality: TMS uses non-drug magnetic brain stimulation, while SPRAVATO delivers the prescription medication esketamine through a nasal spray.
TMS and SPRAVATO approach treatment-resistant depression through different biological and practical pathways. The difference affects treatment experience, side effects, appointment structure, safety screening, and post-treatment restrictions.
How Does TMS Use Non-Drug Magnetic Brain Stimulation?
TMS is a noninvasive brain-stimulation treatment that delivers repeated magnetic pulses through an electromagnetic coil positioned against the scalp.
Repeated Transcranial Magnetic Stimulation, or rTMS, induces small electrical currents in targeted neural circuits. Depression protocols commonly target prefrontal brain regions involved in mood regulation.
TMS patients remain awake during treatment. Standard outpatient rTMS does not require routine anesthesia or sedation.
NeuroStar is one specific TMS medical-device system used for depression treatment. TMS is the broader treatment category, while NeuroStar is a device within that category.
FDA records classify NeuroStar as a transcranial magnetic stimulator rather than a pharmaceutical treatment.
What Is Spravato as an Esketamine Nasal Spray?
SPRAVATO is a prescription nasal spray containing esketamine for specific adult depression indications.
Current U.S. labeling permits SPRAVATO for adult treatment-resistant depression as monotherapy or with an oral antidepressant. SPRAVATO is also indicated with an oral antidepressant for depressive symptoms in adults with MDD and acute suicidal ideation or behavior.
SPRAVATO is administered intranasally under direct healthcare-provider supervision. Patients remain in the certified healthcare setting for at least two hours after administration.
SPRAVATO treatment therefore involves supervised administration and post-treatment monitoring rather than home use.
SPRAVATO contains esketamine, the S-enantiomer of racemic ketamine. SPRAVATO and ketamine are related entities, but they are not interchangeable terms.
How Do TMS and Spravato Mechanisms of Action Differ?
TMS acts through targeted electromagnetic stimulation, while SPRAVATO acts pharmacologically through esketamine.
TMS magnetic pulses stimulate neurons and neural circuits in selected brain regions. NIMH describes rTMS as targeted brain stimulation rather than systemic drug administration.
Esketamine is a noncompetitive N-methyl-D-aspartate, or NMDA, receptor antagonist. NMDA receptors are part of the glutamate neurotransmitter system.
SPRAVATO’s regulatory labeling does not establish one simple antidepressant mechanism that fully explains its clinical effect. The label identifies NMDA-receptor antagonism while stating that the antidepressant mechanism remains unknown.
The accurate contrast is:
TMS targets neural circuitry through magnetic stimulation, while SPRAVATO produces pharmacologic effects through esketamine.
Is TMS or Spravato More Effective for Treatment-Resistant Depression?
Current comparative evidence does not establish TMS or SPRAVATO as universally more effective for treatment-resistant depression.
Both treatments have evidence supporting depressive-symptom improvement. Direct comparative research remains more limited than the separate evidence supporting each treatment individually.
What Does Research Show About TMS Effectiveness?
rTMS has established evidence for reducing depressive symptoms in appropriately selected patients with difficult-to-treat depression.
FDA-cleared TMS systems exist for major depressive disorder in adults who have not achieved satisfactory improvement from prior antidepressant treatment. NeuroStar’s original FDA clearance included adults who had not improved adequately with prior antidepressant medication.
TMS outcomes vary according to patient characteristics, treatment protocol, stimulation target, treatment completion, and other clinical factors.
One manufacturer or registry percentage should therefore not be treated as a universal “TMS success rate” for every patient.
What Does Research Show About Spravato Effectiveness?
SPRAVATO has randomized clinical-trial evidence supporting its use in adult treatment-resistant depression.
The current label includes both adjunctive treatment studies and a newer monotherapy trial. In the monotherapy study, 56 mg and 84 mg SPRAVATO produced statistically greater improvement than placebo at Day 28. Improvement was also observed at approximately 24 hours.
SPRAVATO response is not guaranteed. Clinical benefit varies, and current labeling recommends evaluating therapeutic benefit after the four-week induction phase when deciding whether treatment should continue.
What Do Direct TMS vs Spravato Studies Show?
Direct comparative research suggests that rTMS and intranasal esketamine can both reduce depression severity, but the evidence does not establish a clear universal winner.
Kaster and colleagues published the most directly relevant comparative analysis in eClinicalMedicine in 2025. The investigators used individual participant data from two major clinical trials.
After matching, the analysis included:
- 94 patients receiving rTMS
- 94 patients receiving intranasal esketamine
- 94 patients starting another antidepressant medication
Both rTMS and intranasal esketamine produced greater reductions in depression severity than starting another antidepressant.
rTMS showed greater numerical symptom reduction than intranasal esketamine, but the rTMS-versus-esketamine difference was not statistically significant. The authors described the findings as exploratory and called for prospective head-to-head trials.
Chen and colleagues added real-world evidence in 2026 through a target-trial emulation published in the Journal of Affective Disorders.
The study matched:
- 1,690 rTMS patients
- 1,690 esketamine patients
Overall suicide-related outcomes were broadly comparable. rTMS was associated with lower hospitalization, arrhythmia, and injury risks during parts of follow-up.
The 2026 study was observational and based on electronic health records. It therefore does not provide the same level of causal evidence as a randomized head-to-head trial.
The evidence hierarchy matters:
| Evidence type | What it tells us |
| FDA regulatory evidence | Whether a treatment has established indications and safety requirements |
| Randomized treatment trials | Whether an individual treatment performs better than its study comparator |
| 2025 IPD comparative analysis | Preliminary comparison between rTMS and esketamine using data from separate trials |
| 2026 target-trial emulation | Real-world associations between rTMS and esketamine outcomes |
| Patient or clinic experience | Individual context, not universal comparative proof |
The current evidence supports comparison. It does not support declaring either treatment categorically superior.
Why Is There No Universal “Better” Treatment?
There is no universal better treatment because effectiveness is only one part of the TMS-versus-SPRAVATO decision.
Treatment selection can also depend on:
- Previous antidepressant response
- Previous interventional treatment
- Desired treatment modality
- Medical and neurological history
- Blood-pressure or vascular concerns
- Implanted devices or conductive metal
- Side-effect tolerance
- Appointment availability
- Transportation
- Driving requirements
- Maintenance burden
- Insurance authorization
- Patient preference
These factors need to be considered together rather than ranking treatments from one efficacy endpoint.
Does Spravato Work Faster Than TMS?
SPRAVATO has demonstrated symptom improvement within approximately 24 hours in clinical trials, while standard rTMS usually builds its effect across repeated sessions.
A faster possible onset does not establish greater overall effectiveness.
How Quickly May Spravato Begin Improving Symptoms?
SPRAVATO clinical studies have detected depression-score improvement as early as approximately 24 hours.
In the current monotherapy trial, improvement at Day 2, approximately 24 hours after treatment began, was statistically greater with both 56 mg and 84 mg SPRAVATO than placebo.
Individual response remains variable. A trial-level effect at 24 hours does not mean every patient feels substantially better after one dose.
SPRAVATO treatment decisions therefore evaluate response across the induction phase rather than judging treatment success from one appointment.
How Long Does Standard TMS Usually Take to Work?
Standard TMS response generally develops across a multi-session treatment course rather than one treatment day.
NIMH describes a typical rTMS course as five treatments per week for four to six weeks. Individual sessions commonly last between 3 and 40 minutes, depending on protocol.
Some patients notice changes earlier in the course, while others respond later. One fixed response week does not apply to every patient.
How Does Accelerated TMS Change the Timeline?
Accelerated TMS compresses treatment by delivering multiple stimulation sessions within one day.
NIMH notes that accelerated rTMS protocols can complete an acute course within approximately one week.
Accelerated TMS is not interchangeable with every standard rTMS or NeuroStar protocol. Treatment schedule, stimulation pattern, evidence, and device configuration differ.
Accelerated TMS should therefore be treated as a timing distinction rather than a direct substitute for every standard TMS course.
What Is Treatment Like With TMS vs Spravato?
TMS generally involves frequent shorter outpatient visits without sedation, while SPRAVATO uses fewer dosing days over time but requires longer supervised visits and transportation home.
The practical treatment burden can influence which option fits a patient’s routine.
| Treatment factor | Standard TMS | SPRAVATO |
| Administration | Magnetic coil positioned against scalp | Nasal spray self-administered under supervision |
| Awareness | Awake and alert | Awake, but sedation or dissociation can occur |
| Typical initial frequency | Usually 5 weekdays per week | Twice weekly during weeks 1–4 |
| Visit duration | Protocol dependent; commonly 3–40 minutes for rTMS | Dose administration plus at least 2 hours of monitoring |
| Transportation | Standard treatment generally allows return to normal activities | Transportation home required |
| Driving restriction | No medication-related next-day restriction with standard NeuroStar treatment | No driving until next day after restful sleep |
| Post-treatment observation | No REMS-style drug observation | Mandatory clinical monitoring |
| Ongoing schedule | Course completed over several weeks; follow-up varies | Weekly, then weekly/every two weeks when continued |
What Is the TMS Treatment Schedule and Session Experience?
Standard rTMS typically involves weekday treatment over four to six weeks.
During TMS, a magnetic coil is positioned against the patient’s head. Patients can hear clicking and feel tapping or scalp sensations while magnetic pulses are delivered.
NIMH describes rTMS as an outpatient procedure that does not require anesthesia.
NeuroStar patient materials describe sessions lasting approximately 19–37 minutes for common protocols. Treatment time varies by protocol and clinician recommendation.
Patients remain awake and can generally resume usual activities afterward.
The exact TMS treatment schedule should be determined during clinical treatment planning rather than assumed from one generic protocol.
What Is the Spravato Treatment Schedule and Session Experience?
SPRAVATO treatment begins more frequently and then becomes less frequent when continued treatment remains appropriate.
For adult treatment-resistant depression, the current FDA schedule is:
- Weeks 1–4: twice weekly
- Weeks 5–8: once weekly
- Week 9 onward: every two weeks or once weekly
The maintenance frequency is individualized to the least frequent schedule needed to maintain response or remission.
SPRAVATO patients self-administer the nasal spray under direct healthcare-provider observation.
Patients remain onsite during the required observation period and need transportation home afterward.
Why Does Spravato Require at Least Two Hours of Monitoring?
SPRAVATO requires at least two hours of monitoring because sedation, dissociation, respiratory depression, and blood-pressure changes can occur after administration.
The current FDA label requires healthcare-provider supervision and post-dose monitoring. Blood pressure is reassessed after dosing.
Respiratory status is also monitored because respiratory depression has been reported.
The SPRAVATO REMS program connects these risks to a certified clinical setting rather than home administration.
The two-hour period functions as a minimum observation window. Clinical stability determines whether a patient is ready to leave.
Can You Drive or Return to Work After TMS or Spravato?
Standard TMS generally does not require a medication-related driving restriction, while SPRAVATO patients must not drive until the next day after restful sleep.
NeuroStar treatment does not normally require anesthesia or sedation. Manufacturer safety materials state that patients can generally resume regular activities after treatment.
SPRAVATO has a different restriction because attention, judgment, motor coordination, and alertness can be impaired after treatment.
Current labeling requires patients to avoid driving or hazardous activities until the next day after restful sleep.
A working adult can therefore experience these schedules differently.
A patient who can attend frequent weekday appointments but cannot arrange transportation may find TMS logistics easier. Another patient may prefer fewer weekly treatment days despite longer monitored SPRAVATO visits.
Neither logistical pattern is universally easier.
How Do TMS and Spravato Compare for Side Effects and Safety?
TMS and SPRAVATO have different side-effect profiles. TMS commonly causes local scalp or stimulation-site effects, while SPRAVATO can produce perceptual, neurological, gastrointestinal, cardiovascular, and sedating effects.
Counting side effects does not determine which treatment is safer for one individual. Medical history and treatment-specific risks matter more.
What Are Common TMS Side Effects?
Common rTMS side effects include scalp discomfort, headache, muscle contraction or tingling, and brief dizziness or lightheadedness.
NIMH describes these effects as generally short term. Seizure is possible but uncommon when established safety guidelines are followed.
NeuroStar identifies treatment-site pain or discomfort as its most common adverse effect. NeuroStar reports seizure risk below 0.1% per patient.
TMS does not expose the body to an antidepressant medication as part of the stimulation procedure.
What Are Common Spravato Side Effects?
Common SPRAVATO adverse reactions in adult TRD include dissociation, dizziness, nausea, sedation, vertigo, hypoesthesia, anxiety, lethargy, increased blood pressure, vomiting, feeling drunk, and headache.
SPRAVATO’s psychoactive and systemic effects explain why the treatment requires post-dose monitoring.
Dissociation can involve altered perception or feeling detached. Sedation can reduce alertness. Blood pressure can rise after treatment.
What Serious Risks Differ Between TMS and Spravato?
TMS and SPRAVATO have different serious safety considerations.
The comparison below separates major considerations without treating every precaution as an absolute contraindication.
| TMS | SPRAVATO |
| Rare seizure risk | Sedation |
| Device/metal safety restrictions | Dissociation |
| Neurological and seizure-risk assessment | Respiratory depression |
| Device-specific contraindications | Abuse and misuse risk |
| Worsening mood requires clinical monitoring | Suicidal thoughts and behaviors warning |
| — | Clinically significant blood-pressure increases |
SPRAVATO’s boxed warning covers sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors.
NeuroStar should not be used in patients with certain non-removable conductive metal or stimulator implants in or near the head.
What Is Important to Know About Spravato and Suicidal Symptoms?
SPRAVATO has a specific indication involving depressive symptoms in adults with MDD and acute suicidal ideation or behavior, but the FDA does not state that SPRAVATO prevents suicide.
Current labeling states that SPRAVATO’s effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated.
Improvement after a dose also does not remove the need for hospitalization when clinically warranted.
The distinction matters because rapid improvement in depressive symptoms and proven suicide prevention are not the same claim.
Who May Be a Better Candidate for TMS or Spravato?
TMS or SPRAVATO may be worth discussing under different circumstances, but candidacy depends on clinical evaluation rather than one online checklist.
Treatment history, medical safety, side-effect tolerance, logistics, and personal preference all matter.
When May TMS Be Worth Discussing With a Psychiatrist?
TMS may be worth discussing when a patient has persistent depression despite previous antidepressant treatment and wants to explore a non-drug intervention.
Relevant considerations include:
- Previous antidepressant response
- Medication side effects
- Preference for non-pharmacologic treatment
- Ability to attend repeated sessions
- Seizure history
- Neurological history
- Implanted devices or metal near the head
- Previous TMS treatment
- Insurance requirements
These factors do not automatically establish eligibility.
A psychiatric evaluation reviews diagnosis, treatment history, medications, safety factors, treatment goals, and practical requirements before TMS treatment begins.
When May Spravato Be Worth Discussing With a Psychiatrist?
SPRAVATO may be worth discussing for adults with treatment-resistant depression after inadequate benefit from previous antidepressant treatment.
Relevant considerations include:
- Previous antidepressant trials
- Current depression severity
- Previous treatment response
- Interest in an option with demonstrated early trial effects
- Blood-pressure and vascular history
- Medication interactions
- Substance-use history
- Ability to tolerate dissociation or sedation
- Ability to attend supervised sessions
- Ability to arrange transportation
- Ongoing treatment preferences
SPRAVATO eligibility also depends on FDA contraindications and clinical precautions.
How Do Metal Implants, Seizure History, Blood Pressure, and Other Safety Factors Differ?
TMS and SPRAVATO require different safety screens.
| TMS-specific consideration | SPRAVATO-specific consideration |
| Non-removable conductive metal or certain stimulator implants in or near the head | Aneurysmal vascular disease or arteriovenous malformation |
| Seizure-risk assessment | Previous intracerebral hemorrhage |
| Device-specific safety restrictions | Hypersensitivity to esketamine, ketamine, or excipients |
| Neurological history | Blood-pressure and vascular-risk assessment |
The FDA-approved SPRAVATO contraindications are narrower than its complete precaution list.
Elevated blood pressure, substance-use history, and other factors can require additional assessment without automatically functioning as absolute contraindications.
NeuroStar safety information similarly distinguishes device contraindications from clinical factors requiring caution.
How Long Do TMS and Spravato Benefits Last, and Is Maintenance Needed?
The duration of benefit varies for both treatments, and maintenance or retreatment may be considered according to response and symptom recurrence.
Neither treatment has one universal long-term schedule that applies to every patient.
How Does TMS Maintenance and Retreatment Work?
TMS follow-up varies according to treatment response and whether depressive symptoms return.
NIMH notes that researchers continue to study the best follow-up approaches for sustaining rTMS improvement.
TMS should therefore not be described as requiring permanent maintenance or as permanently resolving depression.
A psychiatrist may discuss monitoring, retreatment, or another maintenance strategy based on the individual clinical course.
How Does Spravato Maintenance Treatment Work?
SPRAVATO has an established maintenance dosing framework for adult TRD.
After twice-weekly induction and weekly treatment through week eight, current labeling permits once-weekly or every-two-week dosing from week nine onward.
The label instructs clinicians to use the least frequent dosing schedule that maintains response or remission.
SPRAVATO does not automatically continue indefinitely. Ongoing treatment requires periodic evaluation of benefit, tolerability, and clinical need.
How Do Cost and Insurance Coverage Differ for TMS and Spravato?
TMS and SPRAVATO costs vary by insurance plan, provider, treatment frequency, maintenance requirements, and patient cost-sharing.
Information not found: no authoritative nationwide source establishes that TMS or SPRAVATO is universally cheaper for every U.S. patient.
What Affects TMS Insurance Approval?
TMS insurance approval can depend on plan-specific requirements.
Common factors can include:
- Diagnosis
- Previous antidepressant treatment
- Medical necessity
- Prior authorization
- Provider network status
- Plan-specific clinical criteria
- Deductible, copay, or coinsurance
Insurance requirements need to be checked against the patient’s actual plan rather than assumed from one insurer’s policy.
What Affects Spravato Insurance Approval?
SPRAVATO coverage also depends on the individual insurance plan and its authorization requirements.
Relevant factors can include:
- FDA-labeled indication
- Documented treatment history
- Prior authorization
- Provider or treatment-center network status
- Dosing frequency
- Copay, deductible, or coinsurance
- Continued-treatment requirements
A national price estimate cannot determine one patient’s actual out-of-pocket cost.
Why Do Treatment Time and Transportation Affect the Real Cost?
Treatment burden extends beyond the direct medical charge.
Patients may also need to consider:
- Appointment frequency
- Total clinic time
- Transportation
- Time away from work
- Childcare or family responsibilities
- Potential maintenance visits
- Copays and coinsurance
- Deductible exposure
Standard TMS requires frequent visits but usually permits normal activity afterward. SPRAVATO visits occur less frequently over time but require at least two hours of observation and transportation home.
These indirect differences can materially affect treatment feasibility even when insurance covers both options.
How Do Doctors Decide Between TMS and Spravato?
Psychiatrists consider diagnosis, previous treatment response, medical and neurological history, safety risks, side-effect tolerance, treatment schedule, transportation, insurance access, and patient preferences.
The decision changes the question from “Which treatment looks better in general?” to “Which treatment fits this patient’s circumstances?”
How Does Treatment History and Previous Response Affect the Decision?
Treatment history helps establish what has already been tried and what happened.
A psychiatrist may review:
- Previous antidepressants
- Adequacy of medication trials
- Medication side effects
- Psychotherapy history
- Augmentation strategies
- Previous TMS
- Previous SPRAVATO or esketamine treatment
- Complete nonresponse
- Partial response
- Previous relapse after improvement
Previous response provides clinical context because not every unsuccessful medication trial represents the same treatment history.
How Does Medical History and Safety Affect the Decision?
Medical history can make one treatment require different precautions than the other.
TMS evaluation focuses particularly on neurological history, seizure risk, implanted devices, and conductive metal near the head.
SPRAVATO evaluation includes vascular history, blood-pressure considerations, medication interactions, substance-use risk, and labeled contraindications.
Clinical review is therefore treatment specific.
A safety factor that matters for SPRAVATO does not automatically matter in the same way for TMS, and the reverse is also true.
How Do Lifestyle and Treatment Preferences Affect the Decision?
Lifestyle can affect whether a medically reasonable treatment is realistically manageable.
Relevant factors include:
- Preference for a non-drug treatment
- Comfort with a psychoactive medication
- Ability to attend five weekday TMS visits
- Ability to attend longer SPRAVATO appointments
- Access to transportation
- Need to drive for work
- Work and family schedules
- Side-effect tolerance
- Interest in ongoing medication-based maintenance
- Ability to complete the recommended course
Frequent TMS appointments may challenge one patient’s work schedule. SPRAVATO’s transportation requirement may create the larger burden for another patient.
Neither logistical pattern is universally easier.
What Questions Should You Ask Your Psychiatrist Before Choosing?
Ask questions that connect the evidence to your specific treatment history and safety profile.
Useful questions include:
- What makes TMS or SPRAVATO more appropriate for my treatment history?
- What evidence is most relevant to patients like me?
- Which safety considerations matter in my case?
- What side effects should I expect from each treatment?
- How will we measure whether treatment is working?
- When would we reassess the treatment plan?
- What happens if I improve only partially?
- What maintenance treatment might be needed?
- How much clinic time should I expect?
- What transportation requirements apply?
- What does my insurance plan require?
These questions move treatment selection from a generic online comparison toward an individualized psychiatric discussion.
How Do We Evaluate TMS and Spravato Options at Lotus Psychiatry & Wellness?
At Lotus Psychiatry & Wellness, we begin with a psychiatric evaluation rather than assuming TMS or SPRAVATO is automatically the next treatment.
Our evaluation can include:
- Current diagnosis and depression symptoms
- Previous medication trials
- Previous treatment response
- Current medications
- Medical history
- Neurological and seizure history
- Blood-pressure and vascular considerations
- Implanted devices or metal
- Side-effect concerns
- Treatment goals
- Schedule and transportation requirements
- Insurance criteria
Our NeuroStar TMS service includes psychiatric review, safety screening, treatment planning, insurance review, and in-office treatment.
Our SPRAVATO service includes supervised administration, blood-pressure assessment, at least two hours of observation, and transportation planning.
We provide psychiatric care through our Boca Raton and Coral Springs locations.
If previous depression treatments have not helped enough, our clinical team can review the evidence, safety factors, and practical requirements before discussing which treatment options may be appropriate.
What Are Common Questions About TMS and Spravato?
The following questions address downstream decisions that often arise after the core TMS-versus-SPRAVATO comparison.
Can You Switch Between TMS and Spravato if One Does Not Work?
Yes. A psychiatrist may consider SPRAVATO after inadequate TMS response or TMS after inadequate SPRAVATO response, but no universal sequencing rule applies to every patient.
The decision depends on response, tolerability, diagnosis, previous treatment, safety factors, and why the first treatment was stopped. Switching treatments requires a new clinical assessment rather than assuming the second treatment will succeed.
Can TMS and Spravato Be Used Together?
Yes, TMS and SPRAVATO may be considered within the same broader treatment plan in selected cases, but evidence does not establish combined treatment as universally more effective.
The evidence base for using both together is smaller than the evidence supporting each treatment separately. Combination treatment therefore requires individualized psychiatric assessment rather than being presented as a standard superior strategy.
Can Spravato Be Used Without an Oral Antidepressant?
Yes. For adult treatment-resistant depression, current U.S. prescribing information allows SPRAVATO as monotherapy or with an oral antidepressant.
For depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior, SPRAVATO remains labeled for use with an oral antidepressant.
This distinction matters because older SPRAVATO webpages and articles may still state that every TRD patient must take an oral antidepressant.
What Should You Remember About Spravato vs TMS?
TMS and SPRAVATO are fundamentally different treatments for difficult-to-treat depression.
TMS uses targeted magnetic brain stimulation without administering an antidepressant drug. SPRAVATO uses intranasal esketamine under direct clinical supervision.
Current comparative evidence does not establish a universal effectiveness winner. The 2025 individual-participant analysis found no statistically significant difference between rTMS and esketamine. The 2026 real-world study adds observational evidence rather than randomized proof.
SPRAVATO has demonstrated earlier treatment effects in clinical trials, including improvement at approximately 24 hours. Standard rTMS usually develops across repeated treatment sessions. Faster onset does not equal greater overall effectiveness.
TMS generally involves more frequent shorter visits, mainly local stimulation-related side effects, and no routine sedation. SPRAVATO involves longer monitored appointments, transportation requirements, and psychoactive or systemic adverse effects.
The more useful question is therefore not “Is TMS or SPRAVATO better?”
The useful question is:
“Which treatment fits my depression history, medical safety profile, treatment goals, side-effect concerns, schedule, transportation needs, maintenance expectations, and insurance situation?”
At Lotus Psychiatry & Wellness, we use those factors to guide the treatment discussion rather than relying on a generic online ranking.